| dc.contributor.author | Kemeriz, Funda | |
| dc.contributor.author | Acar, Emine Müge | |
| dc.contributor.author | Ordu, Melike | |
| dc.date.accessioned | 2022-11-07T11:25:47Z | |
| dc.date.available | 2022-11-07T11:25:47Z | |
| dc.date.issued | 2020 | en_US |
| dc.identifier.citation | Kemeriz, F., Acar, E. M., & Ordu, M. (2020). Omalizumab induced lichenoid drug eruption triggered by sun exposure. Dermatologic Therapy, 33(4), e13542. | en_US |
| dc.identifier.issn | 13960296 | |
| dc.identifier.uri | https://doi.org/10.1111/dth.13542 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12513/4711 | |
| dc.description.abstract | Dear EditorOmalizumab is a humanized monoclonal antibody against humanimmunoglobulin E that is mainly indicated in asthma, allergic rhinitis,chronic spontaneous urticaria and is being increasingly used for otherdermatological diseases, including atopic dermatitis, mastocytosis,hyper-IgE syndrome, and bullous pemphigoid.1,2Rare cutaneous sideeffects, such as itching, skin rash, urticaria, and photosensitivity, havebeen reported to be associated with omalizumab use... | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Blackwell Publishing Inc. | en_US |
| dc.relation.isversionof | 10.1111/dth.13542 | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Omalizumab induced lichenoid drug eruption triggered by sun exposure | en_US |
| dc.type | letter | en_US |
| dc.relation.journal | Dermatologic Therapy | en_US |
| dc.contributor.department | Tıp Fakültesi | en_US |
| dc.contributor.authorID | Emine Müge Acar / 0000-0001-9592-5599 | en_US |
| dc.identifier.volume | 33 | en_US |
| dc.identifier.issue | 4 | en_US |
| dc.identifier.startpage | 1 | en_US |
| dc.identifier.endpage | 2 | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
